This study provides evidence that age- and sex-adjusted yield of screening for TB and corresponding NNS to identify one case of TB among asylum seekers vary strongly depending on country of origin. The dynamic changes in the population screened have implications for the performance of screening programmes, as shown here by higher NNS and lower yield after 2012 compared to preceding time periods. Being able to account for the composition and to react to possibly rapid changes in the population of asylum seekers and to corresponding TB risks is crucial for a responsive and efficient screening programme, but an adequate evidence base is required to guide decision making. We have shown that WHO-reported TB incidence is a predictor of observed yield as the age- and sex-adjusted risk of TB in asylum seekers from countries with a high incidence of TB (> 50 per 100,000) is about four times of those from countries with a low and intermediate incidence (≤ 50 per 100,000). These findings are consistent with other studies on TB in migrant populations [
27,
28], although direct comparability may be limited due to differences in migrant populations, screening protocols, timing of screening, and differences in (or lack of) adjustment strategies in other studies. The discriminatory power of country of origin to determine groups of asylum seekers with higher observed yield, however, decreased with rising cut-offs above 100 per 100,000 (based on WHO-estimated incidence of TB). This is consistent with our data showing how introducing a threshold for screening to increase the pre-test probability affects the sensitivity of screening programmes. This study thus provides a useful first evidence base for decision-making with respect to the development of targeted programs.
Asylum seekers’ country of origin can inform TB screening strategies in mainly two ways. First, country-specific TB data can be used to meaningfully categorise the population to be screened according to the TB incidence in their country of origin. This information may help public health practitioners and health planners to anticipate the consequences of changes in the composition of the screened population on screening efficiency in order to react to underlying population dynamics among asylum seekers (and eventually other forced migrants). It may also help to prioritise asylum seekers from specific countries of origin for screening in times of high immigration in order to allocate scarce resources efficiently and avoid likely unnecessary diagnostics among groups of asylum seekers with low yield. The categories, however, are crude classifications, and reliance on WHO data alone may be misleading especially in fragile states or countries hit by armed conflicts. Reducing uncertainty in decision-making is thus desirable.
We show that, second, combining WHO TB prevalence data as prior information with information on observed yield from historical TB screening data reduced uncertainty of predictions. This approach allowed modelling the expected country-specific yield of TB (posterior distribution) in asylum seekers from 11 countries with greater precision. This information can be practically useful to derive country-specific probabilities for the NNS conditional on a given threshold to inform TB screening programs or guide cost-effectiveness analysis.
Implications for screening programmes
Only few countries perform targeted screening based on TB incidence in the country of origin (e.g. the United Kingdom and Switzerland), and incidence thresholds at which screening is initiated vary, ranging from > 15, > 40, > 50 to > 100 per 100,000 population [
4,
8]. In Germany, no targeted approach exists and all migrants in collective accommodation centers aged 16 years and above undergo compulsory screening (except for pregnant women and children who may be considered for screening based on sub-national regulations [
29]). The results of our study question such indiscriminate screening policies. Other countries use NNS thresholds to decide whether or not to continue or discontinue screening in a given population. In the Netherlands, for example, screening is ceased at an estimated NNS > 2000 [
19]. These thresholds are, however, to a certain degree arbitrary and based on practical experience and the question is how to best choose a threshold. Making decisions about targeted screening programmes requires that questions around sensitivity, timing of screening, and efficiency and cost-effectiveness are addressed.
Our study provides an empirically derived alternative to previous decision-making for or against screening in this context. Limiting screening to a smaller fraction of asylum seekers will, by necessity, miss some rare cases originating from low-incidence countries. The important normative question at the societal or health system level is therefore what is valued as a good or acceptable balance between sensitivity of screening and efficiency and cost-effectiveness of screening. Introducing a threshold means to abandon the traditional idea that entry screening should detect
all TB cases among migrants, which is likely to be an inefficient and perhaps also an unrealistic target. Based on the analysis of change in sensitivity when increasing the pre-test probability, our data suggests that a threshold, based on WHO-reported TB incidence between 50 and 100 per 100,000, would entail the lowest trade-off between loss in sensitivity and efficiency of screening. When introducing a screening threshold at 50 per 100,000, the number of false negative individuals, i.e. asylum seekers with TB going unnoticed, per 1000 individuals is relatively low (although it cannot be ruled out that these would have been also identified due to clinical symptoms or contact investigations). While screening
all individuals upon-entry is an approach that might be feasible in times of low immigration, it is technically, practically, ethically, and economically questionable, especially in times when numbers of immigrants peak. Passive case finding approaches and improved access to primary care [
30] could complement a targeted approach at such a threshold to ensure that the few individuals with TB among those exempt from screening are noticed as soon as an infection turns into disease and becomes symptomatic. If the purpose of a programme is to increase efficiency, the threshold could probably be even increased to 100 per 100,000 without substantial loss in sensitivity.
Furthermore, the estimated country-specific proportion of detected TB cases conditional on NNS-based cut-offs allows assessing the impact on screening efficiency when using
different NNS thresholds for screening of asylum seekers from a given country. The data provided by our study can be used to calculate such targets and estimate marginal costs of finding additional TB cases in asylum seekers from low-incidence countries to guide such decisions. Even with universal screening and more if screening is selective, the country has to expect that some TB cases will be undetected and will appear after entry. Research in a large cohort of immigrants to the United Kingdom has shown that the risk of TB incidence among immigrants screened negative before entry is highest during the first two to 4 years after immigration [
17]. Furthermore, the proportion of cases detected before entry are relatively low compared to those developing TB after immigration [
17]. Data from Germany is consistent with these findings, showing that cases detected upon entry are only a small fraction of cases becoming incident in the following years [
31]. Providing universal access to health care and social protection [
32] and complementing targeted upon-entry screening with adequate (i.e. culturally, ethically and economically acceptable) programmes for post-migration follow-up for TB [
16,
33] is thus of crucial importance, also for TB control in Germany.
Our study adds further complexity to the question of “pre-entry, post-entry or no tuberculosis screening” [
11] among immigrants by considering asylum seekers as a socially constructed, heterogeneous group [
16]. Asking
whom to screen among asylum seekers instead of
whether or not to screen [
11] all would be of special importance for countries at the external borders of the EU such as Italy, Greece and Spain with a high number of forced migrants arriving every year. These countries currently apply an ‘all or nothing principle’ with respect to TB screening (Greece and Spain actively screening all, and Italy none of the incoming refugees [
8,
9]). A more nuanced approach would consider the expected TB prevalence based on asylum seekers’ countries of origin. Such an approach should be closely linked with the question of the design and optimal timing for post-migration follow-up [
17,
33] screening for asylum seekers from countries at highest risk for TB [
16].
Beyond efficiency, our study has also implications with respect to equity and ethical aspects. Screening strategies that take into account country-specific risk avoid overprovision of services [
34], allow to allocate resources where needs are highest (vertical equity), and are therefore an essential step towards tailored and appropriate high-value care [
35,
36] for asylum seekers. Targeted screening is, however, a double-edged sword. Ethical implications from strategies targeting asylum seekers based on country of origin are to avoid stigmatisation. This requires that clinicians, policy makers, politicians and public health services effectively communicate the fact that these groups area “at higher risk” of having TB, not “a higher risk” for importing TB [
37].
Future research
Prediction algorithms for targeted screening could be further improved by combining clinical, diagnostic [
2,
13] and country-specific parameters. A combination with age, sex and socioeconomic status could further improve estimates of expected yield. This is especially relevant to further decrease the potential loss in sensitivity, and reduce the trade-off between sensitivity and high pre-test probability. Clinical information on co-morbidities (e.g. HIV, or diabetes) and socioeconomic factors were, however, not available in our data. The empirical derivation of such algorithms and their validation is further complicated because TB is a rare disease (thus, large samples are required) and available data often contain little detail on personal characteristics. We were able to estimate parameters for only 11 of 81 countries with reasonable precision. Pooling of large datasets across countries with comparable screening protocols is needed to enable further data analysis, especially as the overall yield in our study was lower than those reported in other studies on asylum seekers [
3,
10]. This would allow replicating and applying our approach to other countries of origin. Initiatives such as the E-DETECT TB project co-funded by the European Commission [
8] may be instrumental to this end. Furthermore, cost-effectiveness studies based on the data on thresholds and NNS provided in this study, or in studies with a larger sample size with more TB cases could be performed to generate further guidance for the decision-making towards targeted screening programmes.
Strengths and limitations
We used a mono-centric data source spanning 14 years of upon-entry TB screening in one of the largest German federal states, which is comparable in size and population to Belgium or the Netherlands. The sample can be seen as representative with respect to age and sex distribution for asylum-seekers in Germany. The composition of the target population with respect to countries of origin may vary between federal states due to administrative procedures in the asylum process. However, this variation affects only few countries of origin, and the majority of asylum seekers are distributed to federal states based on a quasi-random administrative process [
29]. It is hence likely that the composition of the population over 13 years resembles those of Germany as a whole, although direct comparison with administrative data provided by the Federal Agency for Migration and Refugees is difficult.
We only focused on active TB cases as the primary aim of upon-entry screening is to avoid transmissions in asylum seekers’ shelters. Including asylum seekers with latent TB in the analysis would have increased the yield estimates, but would have been less relevant for informing screening programmes.
Despite the large sample used the generalizability to other EU countries may be limited due to the heterogeneity in screening protocols [
8]. It may also be the case that countries of first arrival of asylum seekers in Southern Europe have different (and higher) screening yields. However, we are not aware of any systematic analysis of differences in screening yield depending on the migration trajectory.
Given the low yield of TB screening and the uncertainty around estimates of observed screening yield, external evidence on TB burden should generally be considered in decisions for or against screening of asylum seekers from a given country since the uncertainty can be reduced. Depending on the general agreement between prevalence in country of origin and empirical screening data this may be sensible for some countries (e.g. Syria), but not for all countries (e.g. Afghanistan). It generally appears sensible where no or very sparse evidence exists from screening studies, where estimated TB prevalence and observed screening yield are not in conflict, and where no evidence exists that the screened population is substantially different from the general population with respect to TB risk. It might be sensible to add some “extra-uncertainty” to the country-specific prior (i.e., not applying the prevalence as the prior distribution 1:1 but to make it less informative) to consider the possibility that asylum and general populations differ with respect to TB risk. We have shown that WHO data is more reasonable to use as prior information instead of GBD estimates. The uncertainty in WHO data is a study limitation, and using period-averaged estimates as proxy of country-specific TB risk may not reflect the “true” risk at time of emigration. But this approach seemed as both practicable and reasonable for the vast population in our sample. Although GBD estimates appear more robust, and thus intuitively better, their narrow uncertainty bounds imply such a high certainty that no other source of information (in this case observed TB prevalence taken from screening data) was able to influence the distribution of data. This was not unproblematic as the deviance between observed screening data and prior information was higher for GBD data than for WHO data. The reason for this may be the use of period prevalences for both WHO (1994–2014) and German screening data (2002–2015), while using point prevalences (2015) for GBD data.